Literature DB >> 22115426

Predominance of human lymphotropic T cell virus type 2 subtype B in urban populations of Argentina.

Carolina A Berini1, Maria E Eirin, Cecilia M Delfino, Mercedes Weissenbacher, Mirna M Biglione.   

Abstract

Human T-lymphotropic virus subtype b (HTLV-2b) infection has been described among aborigines from Northern Argentina, while HTLV-2a has been described in an injecting drug user (IDU) from a Central region, similar to the situation in Spain, the United States, and Brazil. In this study, 22 of the 26 strains analyzed from blood donors and HIV-1(+) individuals were HTLV-2b (84.6%) clustering with Amerindian references, while 4 HIV-1(+) (15.4%) were HTLV-2a. HTLV-2a sequences were closely related to Brazilian references in contrast to the previous Argentinean IDU strain that clustered with Africans and Amerindians from North America. In summary, these findings show that HTLV-2b is the major strain circulating in an urban population of Argentina. HTLV-2a/b could have been introduced from endemic South American countries such as Brazil and because of contact with other populations such as IDUs from Europe despite its introduction due to the increasing internal migration of aborigines to large urban centers. Considering this results and recent data about the dissemination of HTLV-1 in residents of Buenos Aires city, new studies among non-at-risk groups for HTLV-1/2 infection should be performed.

Entities:  

Mesh:

Year:  2012        PMID: 22115426     DOI: 10.1089/AID.2011.0311

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  1 in total

1.  Silent dissemination of HTLV-1 in an endemic area of Argentina. Epidemiological and molecular evidence of intrafamilial transmission.

Authors:  María C Frutos; Rene Gastaldello; Marcos Balangero; Carlos Remondegui; Sebastián Blanco; Koko Otsuki; Ana Carolina Paulo Vicente; David Elías; Arnaldo Mangeaud; Silvia Nates; Sandra Gallego
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.